Guest: Jonathan Kimmelman, PhD
Host: Maurice Pickard, MD
What should be done if research subjects become ill from phase 1 clinical trials? Dr. Jonathan Kimmelman, assistant professor of the Biomedical Research unit at McGill University says most programs do not provide health care or compensation from loss of time from work or for pain and suffering. He also tells host Dr. Pickard that data is viewed as proprietary and is not shared. With trials continuing to move to for-profit companies, is federal oversight being lost? Furthermore, does this lead to increased risk for all those concerned?
Clinician's Roundtable